---
schema_version: "secwatch.filing_event.v1"
accession: "0001411690-23-000008"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T06:52:04.049446+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bionano Q4 revenue $8.2M (+30% YoY); FY2022 rev $27.8M (+55%)

## Summary
- Q4 revenue $8.2M, up 30% from Q4 2021; FY2022 revenue $27.8M, up 55% from FY2021.
- Installed base of Saphyr systems reached 240 at YE 2022, a 46% increase over 2021.
- Acquired Purigen Biosystems to accelerate OGM adoption; deal value not disclosed.
- Achieved all 2022 ELEVATE! milestones; next-gen OGM system commercial launch planned H1 2023.
- 2023 revenue outlook provided but specific guidance range not included in this excerpt.

## SEC filing metadata
- accession: 0001411690-23-000008
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000141169023000008/0001411690-23-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000141169023000008/bngo-20230309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411690-23-000008
- JSON: https://secwatch.observer/filing/0001411690-23-000008.json
- Plain text: https://secwatch.observer/filing/0001411690-23-000008.txt

## Key facts
- Earnings Releases
  Bionano Genomics, Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $8.2 million.
  - Period: fourth quarter and fiscal year ended December 31, 2022
  - Revenue: $8.2 million
  - Result: reported results
  source text: Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Bionano Genomics Reports Fourth Quarter and Full Year 2022 Results and Provides Revenue Outlook for 2023 • Q4 revenue was $8.2 million , which represents a 30% increase over Q4 2021 • 2022 revenue was $27.8 million , which represents a 55% increase over year end 2021 • Reached installed base of 240 Saphyr®
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000141169023000008/0001411690-23-000008-index.htm
- Earnings Releases
  Bionano Genomics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue $27.8 million.
  - Period: fourth quarter and full year ended December 31, 2022
  - Revenue: $27.8 million
  - Result: reported results
  source text: Full year 2022 revenue was $27.8 million , an increase of 55% compared to 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000141169023000008/0001411690-23-000008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.